ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0877

Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.

Rodrigo García Salinas1, Gisel Reyes-Jara2, Felicia Almada3, Juan Arguello2 and Sebastian Magri4, 1Hospital Italiano La Plata, La Plata, Argentina, 2Hospital Italiano de La Plata, La Plata, Argentina, 3Hospital Italiano de La Plata, La Plara, Argentina, 4Hospital Italiano La Plata, Melchor Romero, Argentina

Meeting: ACR Convergence 2025

Keywords: Psoriatic arthritis, Therapy, alternative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies (0873–0878)

Session Type: Abstract Session

Session Time: 11:00AM-11:15AM

Background/Purpose: The transition from psoriasis (Pso) to psoriatic arthritis (PsA) presents an opportunity for early intervention and preventive strategies in high-risk patients with arthralgia. Objectives: To estimate the frequency of treatment initiation in patients with arthralgia at risk of progression to PsA (ARP-PsA), compare characteristics between treated and untreated groups, and analyze progression to PsA after one year.

Methods: A prospective cohort study included patients >18 years with arthralgia and no prior PsA diagnosis. Baseline assessments included laboratory tests, radiography, ultrasound, and clinical evaluation (reuma-check). Data on demographics, joint count, global VAS, HAQ, Pso, and family history (FH) were collected. ARP-PsA was defined as arthralgia + Pso and/or FH. Treatment initiation with NSAIDs and/or DMARDs was evaluated, as well as progression to PsA after one year, based on our previous published research (1). High-risk factors (Pso >15 years, Pso + FH, ultrasound synovitis/enthesopathy) were assessed. Statistical tests included, descriptive analisis, chi-squared, Fisher’s exact, Student’s t-test, and Mann-Whitney.

Results: Of 1419 patients with arthralgia, 8.4% (n=119) met ARP-PsA criteria. Among them, 41% initiated treatment: NSAIDs in 22%, DMARDs in 21% (56% methotrexate), and corticosteroids in 4%. Treated patients more frequently had psoriasis (60% vs. 24%, p=0.001), while other demographic, clinical, imaging, and laboratory variables showed no significant differences (Table 1). At one-year follow-up, 29% (n=34) progressed from arthralgia to clinically classified PsA, and 62% of them had received treatment (35% NSAIDs, 26% DMARDs) (Figure 1). Among those meeting at least one high-risk criterion (36% of ARP-PsA), 65% were treated.

Conclusion: In ARP-PsA patients, 41% initiated treatment, with psoriasis being the key differentiating factor. Of those progressing to PsA, 62% were under treatment, highlighting the importance of early therapeutic intervention, particularly in patients with high-risk features.Bibliography(1) Rodrigo GS, Sebastian M, Jonatan M, Rosario J, Ronald P, Santiago R, Xenofon B. Arthralgia with risk of progression to psoriatic arthritis: role of clinical assessments and ultrasound as prognostic factors. Rheumatology (Oxford). 2024 Oct 15:keae562. doi: 10.1093/rheumatology/keae562. Epub ahead of print. PMID: 39404885.

Supporting image 1Table 1: Characteristics of ARP-PsA Patients Based on Treatment Initiation

Supporting image 2Figure 1


Disclosures: R. García Salinas: AbbVie/Abbott, 2, 5, 6, Adium, 2, 5, 6, Amgen, 2, 5, 6, Biogen, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Eli Lilly, 2, 5, 6, GlaxoSmithKlein(GSK), 2, 5, 6, Janssen, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Raffo, 2, 5, 6, Roche, 2, 5, 6, UCB, 2, 5, 6; G. Reyes-Jara: None; F. Almada: None; J. Arguello: None; S. Magri: None.

To cite this abstract in AMA style:

García Salinas R, Reyes-Jara G, Almada F, Arguello J, Magri S. Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis. [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/therapeutic-approach-in-patients-with-arthralgia-at-risk-of-progression-to-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-approach-in-patients-with-arthralgia-at-risk-of-progression-to-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology